GlassScriptPhysician profile
Erica Bell
NPI 1538543384
$1,277.80
in general payments reported to CMS, 2019-2025
18 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.02 · 2022: $233 · 2023: $318 · 2024: $354 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.71 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $221.61 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $209.76 | 2021-2025 | Bexsero, Rotarix, Shingrix |
| Lilly USA, LLC | $151.58 | 2023-2025 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $95.98 | 2024 | Dupixent |
| Sanofi Pasteur INC. | $86.57 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $73.86 | 2022-2023 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $65.21 | 2022 | |
| Alkermes, INC. | $64.00 | 2024-2025 | Vivitrol |
| Sanofi-Aventis U.S. LLC | $57.48 | 2023 | |
| Genzyme Corporation | $41.67 | 2023-2025 | |
| Dexcom, INC. | $39.41 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.20 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.87 | 2024 | Farxiga |
| Amgen INC. | $25.47 | 2021-2025 | Repatha, Otezla |
| Electromed, INC. | $23.32 | 2024 | Smartvest |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $22.54 | 2025 | Vest Therapy Und |
| Pfizer INC. | $21.51 | 2025 | |
| Exact Sciences Corporation | $14.76 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.